Literature DB >> 25335433

Regulatory T cells from active non-segmental vitiligo exhibit lower suppressive ability on CD8+CLA+ T cells.

Mao Lin1, Bao-Xiang Zhang2, Nan Shen2, Xue-Jiao Dong2, Ci Zhang2, Xiao-Yi Qi3, Jie Zhu4, Yu-Zhong Li4, Mao-Qiang Man5, Cai-Xia Tu1.   

Abstract

BACKGROUND: Recent studies have shown that vitiligo is a T-cell mediated autoimmune disease. Skin-homing cytotoxic T lymphocytes expressing cutaneous lymphocyte-associated antigen (CLA) have been suggested to be responsible for the destruction of melanocytes in vitiligo. An aberration in the suppressive function of regulatory T cells (Tregs) has been reported in vitiligo patients. However, whether the weakened suppressive ability of the Tregs contributes to hyper-activated skin homing CD8(+)CLA(+) T cells remains to be determined.
OBJECTIVES: To investigate the inhibition of circulating Tregs on the proliferation of autologous CD8(+)CLA(+) T cells in non-segmental vitiligo patients.
METHODS: CD8(+)CLA(+) T cells and Tregs were obtained from the peripheral blood of 13 non-segmental vitiligo patients and 7 controls. The proliferative responses of CD8(+)CLA(+) T cells were assessed in the absence or presence of autologous Tregs, and the levels of Transforming Growth Factor β1(TGF-β1) and IL-10 in culture supernatants were detected by enzyme-linked immunosorbent assay.
RESULTS: The proliferative responses of circulating CD8(+)CLA(+) T cells in the presence of Tregs were significantly higher in the active vitiligo than in the stable vitiligo and control groups. Tregs from active vitiligo patients exhibited a lower inhibitory effect on proliferation of CD8(+)CLA(+) T cells. The levels of TGF-β1 produced by Tregs were significantly lower in active vitiligo than other groups and anti-TGF-β1 antibodies could abrogate the suppressive function of Tregs.
CONCLUSIONS: The functional activity of Tregs is compromised in active vitiligo patients. TGF-β1 plays an important role in the autoimmune mechanism of the disease.

Entities:  

Keywords:  CD8+ T cell; cutaneous lymphocyte-associated antigen; regulatory T cells; vitiligo

Mesh:

Substances:

Year:  2014        PMID: 25335433     DOI: 10.1684/ejd.2014.2436

Source DB:  PubMed          Journal:  Eur J Dermatol        ISSN: 1167-1122            Impact factor:   3.328


  8 in total

1.  Effect of combination of fractional CO2 laser and narrow-band ultraviolet B versus narrow-band ultraviolet B in the treatment of non-segmental vitiligo.

Authors:  Mohamed Bakr El-Zawahry; Naglaa Sameh Zaki; Marian Youssry Wissa; Marwah Adly Saleh
Journal:  Lasers Med Sci       Date:  2017-07-26       Impact factor: 3.161

2.  Catecholamines' accumulation and their disturbed metabolism at perilesional site: a possible cause of vitiligo progression.

Authors:  Sushma Tanwar; Vishal Thakur; Alka Bhatia; Davinder Parsad
Journal:  Arch Dermatol Res       Date:  2022-02-28       Impact factor: 3.017

3.  A case series pilot study on the combination of 5-aminolevulinic acid and photodynamic therapy (ALA-PDT) for treatment of vitiligo.

Authors:  YunJie Zhang; Hui Lin; XiaoJuan Guo; XianBiao Zou
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

Review 4.  Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity.

Authors:  Yinghan Wang; Shuli Li; Chunying Li
Journal:  Med Sci Monit       Date:  2019-02-06

5.  Identification of the Role of Wnt/β-Catenin Pathway Through Integrated Analyses and in vivo Experiments in Vitiligo.

Authors:  Si-Jia Zhao; Hong Jia; Xiu-Lian Xu; Wen-Bo Bu; Qian Zhang; Xi Chen; Juan Ji; Jian-Fang Sun
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-09-01

Review 6.  Current Concepts of Vitiligo Immunopathogenesis.

Authors:  Nika Hlača; Tina Žagar; Marija Kaštelan; Ines Brajac; Larisa Prpić-Massari
Journal:  Biomedicines       Date:  2022-07-08

7.  The time window for the reversal of depigmentation from aggravation to recovery in a non-small-cell lung cancer patient with pre-existing vitiligo using anti-programmed cell death-1 therapy: A case report.

Authors:  Zhiru Gao; Yinghui Xu; Jianjiao Zu; Xu Wang; Chao Sun; Shi Qiu; Ye Guo; Kewei Ma
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

Review 8.  Targeting the PD-1/PD-L1 Axis in Human Vitiligo.

Authors:  Marcella Willemsen; Cornelis J M Melief; Marcel W Bekkenk; Rosalie M Luiten
Journal:  Front Immunol       Date:  2020-11-06       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.